- Home
- CUTR vs BIVI Comparison
CUTR vs BIVI Comparison
Compare CUTR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUTR
- BIVI
- Stock Information
- Founded
- CUTR 1988
- BIVI 2013
- Country
- CUTR United States
- BIVI United States
- Employees
- CUTR N/A
- BIVI N/A
- Industry
- CUTR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- CUTR Health Care
- BIVI Health Care
- Exchange
- CUTR Nasdaq
- BIVI Nasdaq
- Market Cap
- CUTR 30.5M
- BIVI 20.4M
- IPO Year
- CUTR 2004
- BIVI N/A
- Fundamental
- Price
- CUTR $0.75
- BIVI $2.98
- Analyst Decision
- CUTR Buy
- BIVI Strong Buy
- Analyst Count
- CUTR 4
- BIVI 2
- Target Price
- CUTR $5.33
- BIVI $40.00
- AVG Volume (30 Days)
- CUTR 298.4K
- BIVI 74.2K
- Earning Date
- CUTR 11-06-2024
- BIVI 11-06-2024
- Dividend Yield
- CUTR N/A
- BIVI N/A
- EPS Growth
- CUTR N/A
- BIVI N/A
- EPS
- CUTR N/A
- BIVI N/A
- Revenue
- CUTR $169,188,000.00
- BIVI N/A
- Revenue This Year
- CUTR N/A
- BIVI N/A
- Revenue Next Year
- CUTR $6.35
- BIVI N/A
- P/E Ratio
- CUTR N/A
- BIVI N/A
- Revenue Growth
- CUTR N/A
- BIVI N/A
- 52 Week Low
- CUTR $0.65
- BIVI $2.07
- 52 Week High
- CUTR $9.12
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- CUTR 44.04
- BIVI 49.36
- Support Level
- CUTR $0.67
- BIVI $2.43
- Resistance Level
- CUTR $0.85
- BIVI $3.28
- Average True Range (ATR)
- CUTR 0.08
- BIVI 0.24
- MACD
- CUTR 0.03
- BIVI 0.08
- Stochastic Oscillator
- CUTR 52.05
- BIVI 60.44
About CUTR Cutera Inc.
Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.